Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hikma Pharmaceuticals Plc ADR (OP: HKMPY ) 46.60 UNCHANGED Streaming Delayed Price Updated: 9:37 AM EST, Nov 13, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Hikma Pharmaceuticals Plc ADR Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production September 06, 2024 Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. Via Benzinga Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices August 28, 2024 Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and... Via Benzinga Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa January 08, 2024 From Guardant Health, Inc. Via Business Wire Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape June 12, 2023 The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March. Methotrexate is an injected medication utilized to treat... Via Benzinga Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region December 26, 2022 From Junshi Biosciences Via GlobeNewswire Friday Markets News March 25, 2022 Methane leaks in the Permian Basin are 6 times higher than estimates. Via Talk Markets Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab) August 27, 2021 From Bio-Thera Solutions, Ltd. Via Business Wire Summer Friday June 25, 2021 The stock market tried for another record after yesterday's late blowout over the infrastructure deal. Via Talk Markets Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
